Jump to content

CHEK1: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 17: Line 17:


===G2/M transition===
===G2/M transition===
In response to DNA damage, Chk1 is an important signal transducer for G2/M checkpoint activation. Activation of Chk1 holds the cell in the G2 phase until ready to enter the mitotic phase. This delay allows time for DNA to repair or cell death to occur if DNA damage is irreversible. Chk1 must inactivate in order for the cell to transition from the G2 phase into mitosis, Chk1 expression levels are mediated by regulatory proteins.
In response to DNA damage, Chk1 is an important signal transducer for G2/M checkpoint activation. Activation of Chk1 holds the cell in the G2 phase until ready to enter the mitotic phase. This delay allows time for DNA to repair or cell death to occur if DNA damage is irreversible<ref>{{cite journal|last=Meuth|first=M|title=Chk1 suppressed cell death|journal=Cell Div|date=2010|doi=10.1186/1747-1028-5-21|pmid=20813042}}</ref> . Chk1 must inactivate in order for the cell to transition from the G2 phase into mitosis, Chk1 expression levels are mediated by regulatory proteins.


===M phase===
===M phase===
Line 43: Line 43:
Chk1 has a central role in coordinating the DNA damage response and therefore is an area of great interest in oncology and the development of cancer therapeutics.<ref name="pmid22435685">{{cite journal | author = Goto H, Izawa I, Li P, Inagaki M | title = Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? | journal = Cancer Sci. | volume = 103 | issue = 7 | pages = 1195–200 | year = 2012 | pmid = 22435685 | doi = 10.1111/j.1349-7006.2012.02280.x }}</ref> Initially Chk1 was thought to function as a tumor suppressor due to the regulatory role it serves amongst cells with DNA damage. However, there has been no evidence of homozygous loss of function mutants for Chk1 in human tumors.<ref name=pmid23613359 /> Instead, Chk1 has been shown to be overexpressed in a numerous tumors including breast, colon, liver, gastric and nasopharyngeal carcinoma.<ref name=pmid23613359 /> There is a positive correlation with Chk1 expression and tumor grade and disease recurrence suggesting Chk1 may promote tumor growth.<ref name=pmid23613359 /><ref name=pmid23508805 /><ref name=pmid22435685 /> Chk1 is essential for cell survival and through high levels of expressions in tumors the function may be inducing tumor cell proliferation. Studies have shown complete loss of Chk1 suppresses chemically induce carcinogenesis however Chk1 haploinsufficiency results in tumor progression.<ref name=pmid23508805 />
Chk1 has a central role in coordinating the DNA damage response and therefore is an area of great interest in oncology and the development of cancer therapeutics.<ref name="pmid22435685">{{cite journal | author = Goto H, Izawa I, Li P, Inagaki M | title = Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? | journal = Cancer Sci. | volume = 103 | issue = 7 | pages = 1195–200 | year = 2012 | pmid = 22435685 | doi = 10.1111/j.1349-7006.2012.02280.x }}</ref> Initially Chk1 was thought to function as a tumor suppressor due to the regulatory role it serves amongst cells with DNA damage. However, there has been no evidence of homozygous loss of function mutants for Chk1 in human tumors.<ref name=pmid23613359 /> Instead, Chk1 has been shown to be overexpressed in a numerous tumors including breast, colon, liver, gastric and nasopharyngeal carcinoma.<ref name=pmid23613359 /> There is a positive correlation with Chk1 expression and tumor grade and disease recurrence suggesting Chk1 may promote tumor growth.<ref name=pmid23613359 /><ref name=pmid23508805 /><ref name=pmid22435685 /> Chk1 is essential for cell survival and through high levels of expressions in tumors the function may be inducing tumor cell proliferation. Studies have shown complete loss of Chk1 suppresses chemically induce carcinogenesis however Chk1 haploinsufficiency results in tumor progression.<ref name=pmid23508805 />


Due to the possibility of Chk1 involvement in tumor promotion, the kinase and related signaling molecules may be potentially effective therapeutic targets. Cancer therapies utilize DNA damaging therapies such as chemotherapies and ionizing radiation to inhibit tumor cell proliferation and induce cell cycle arrest.<ref name="pmid21034966">{{cite journal | author = Smith J, Tho LM, Xu N, Gillespie DA | title = The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer | journal = Adv. Cancer Res. | volume = 108 | issue = | pages = 73–112 | year = 2010 | pmid = 21034966 | doi = 10.1016/B978-0-12-380888-2.00003-0 }}</ref> Tumor cells with increased levels of Chk1 acquire survival advantages due to the ability to tolerate a higher level of DNA damage. Therefore Chk1 may contribute to chemotherapy resistance.<ref name="pmid19034564">{{cite journal | author = Liang Y, Lin SY, Brunicardi FC, Goss J, Li K | title = DNA damage response pathways in tumor suppression and cancer treatment | journal = World J Surg | volume = 33 | issue = 4 | pages = 661–6 | year = 2009 | pmid = 19034564 | doi = 10.1007/s00268-008-9840-1 }}</ref> In order to optimize chemotherapies, Chk1 must be inhibited to reduce the survival advantage.<ref name="pmid24140082">{{cite journal | author = McNeely S, Beckmann R, Bence Lin AK | title = CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy | journal = Pharmacol. Ther. | volume = 142 | issue = 1 | pages = 1–10 | year = 2014 | pmid = 24140082 | doi = 10.1016/j.pharmthera.2013.10.005 }}</ref> By inhibiting Chk1, cancer cells lose the ability to repair damaged DNA which allows chemotherapeutic agents to work more effectively. Combining DNA damaging therapies such as chemotherapy or radiation treatment with Chk1 inhibition enhances targeted cell death and provides synthetic lethality<ref>{{cite journal|last=Toledo|first=L|coauthors=Murga M, Fernandez-Capetillo O|title=Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs.|journal=Mol Oncol 2011|date=2011|doi=10.1016/j.molonc.2011.07.002|pmid=21820372}}</ref> . Many cancers rely on Chk1 mediated cell cycle arrest heavily especially if cancers are deficient in p53<ref>{{cite journal|last=Chen|first=Z|coauthors=et al|title=Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.|journal=Int J Cancer|date=2006|pmid=17019715}}</ref> . Approximately 50% of cancers possess p53 mutations illustrating the dependence that many cancers may have on the Chk1 pathway<ref>{{cite journal|last=Maugeri-Saccà|first=M|coauthors=Bartucci M, De Maria R|title=Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy.|journal=Cancer Treat Rev.|date=2004|volume=39|issue=5|pages=525-533|doi=10.1016/j.ctrv.2012.10.007|pmid=23207059}}</ref> <ref>{{cite journal|last=Tao|first=ZF|coauthors=Lin NH|title=Chk1 inhibitors for novel cancer treatment|journal=Anticancer Agent Med Chem|date=2006|pmid=16842237}}</ref> <ref>{{cite journal|last=Ma|first=CX|coauthors=Janetka JW|title=Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.|journal=Trends Mol Med|date=2011|pmid=21087899}}</ref>. Inhibition of Chk1 allows selective targeting of p53 mutant cells as Chk1 levels are more likely to highly expressed in tumor cells with p53 deficiencies<ref>{{cite journal|last=Goto|first=H|coauthors=Izawa I, Li P, Inagaki M|title=Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?|journal=Cancer Sci|date=2012|volume=103|issue=7|doi=10.1111/j.1349-7006.2012.02280|pmid=22435685}}</ref> . Even though this method of inhibition is highly targeted, recent research has shown Chk1 also has a role in the normal cell cycle<ref>{{cite journal|last=Thompson|first=R|coauthors=Eastman A|title=The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design|journal=Br J Clin Pharmacol|date=2013|volume=76|issue=3|doi= 10.1111/bcp.12139.|pmid=23593991}}</ref>. Therefore off-target effects and toxicity associated with combination therapies using CHk1 inhibitors must be considered during development of novel therapies<ref>{{cite journal|last=Dent|first=P|coauthors=Tang Y, Yacoub A, Dai Y et al|title=CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.|journal=Mol Interv.|date=2011|doi=10.1124/mi.11.2.11|pmid=21540473}}</ref> .
Due to the possibility of Chk1 involvement in tumor promotion, the kinase and related signaling molecules may be potentially effective therapeutic targets. Cancer therapies utilize DNA damaging therapies such as chemotherapies and ionizing radiation to inhibit tumor cell proliferation and induce cell cycle arrest.<ref name="pmid21034966">{{cite journal | author = Smith J, Tho LM, Xu N, Gillespie DA | title = The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer | journal = Adv. Cancer Res. | volume = 108 | issue = | pages = 73–112 | year = 2010 | pmid = 21034966 | doi = 10.1016/B978-0-12-380888-2.00003-0 }}</ref> Tumor cells with increased levels of Chk1 acquire survival advantages due to the ability to tolerate a higher level of DNA damage. Therefore Chk1 may contribute to chemotherapy resistance.<ref name="pmid19034564">{{cite journal | author = Liang Y, Lin SY, Brunicardi FC, Goss J, Li K | title = DNA damage response pathways in tumor suppression and cancer treatment | journal = World J Surg | volume = 33 | issue = 4 | pages = 661–6 | year = 2009 | pmid = 19034564 | doi = 10.1007/s00268-008-9840-1 }}</ref> In order to optimize chemotherapies, Chk1 must be inhibited to reduce the survival advantage.<ref name="pmid24140082">{{cite journal | author = McNeely S, Beckmann R, Bence Lin AK | title = CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy | journal = Pharmacol. Ther. | volume = 142 | issue = 1 | pages = 1–10 | year = 2014 | pmid = 24140082 | doi = 10.1016/j.pharmthera.2013.10.005 }}</ref> By inhibiting Chk1, cancer cells lose the ability to repair damaged DNA which allows chemotherapeutic agents to work more effectively. Combining DNA damaging therapies such as chemotherapy or radiation treatment with Chk1 inhibition enhances targeted cell death and provides synthetic lethality<ref>{{cite journal|last=Toledo|first=L|coauthors=Murga M, Fernandez-Capetillo O|title=Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs.|journal=Mol Oncol 2011|date=2011|doi=10.1016/j.molonc.2011.07.002|pmid=21820372}}</ref> . Many cancers rely on Chk1 mediated cell cycle arrest heavily especially if cancers are deficient in p53<ref>{{cite journal|last=Chen|first=Z|coauthors=et al|title=Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.|journal=Int J Cancer|date=2006|pmid=17019715}}</ref> . Approximately 50% of cancers possess p53 mutations illustrating the dependence that many cancers may have on the Chk1 pathway<ref>{{cite journal|last=Maugeri-Saccà|first=M|coauthors=Bartucci M, De Maria R|title=Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy.|journal=Cancer Treat Rev.|date=2004|volume=39|issue=5|pages=525-533|doi=10.1016/j.ctrv.2012.10.007|pmid=23207059}}</ref> <ref>{{cite journal|last=Tao|first=ZF|coauthors=Lin NH|title=Chk1 inhibitors for novel cancer treatment|journal=Anticancer Agent Med Chem|date=2006|pmid=16842237}}</ref> <ref>{{cite journal|last=Ma|first=CX|coauthors=Janetka JW|title=Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.|journal=Trends Mol Med|date=2011|pmid=21087899}}</ref>. Inhibition of Chk1 allows selective targeting of p53 mutant cells as Chk1 levels are more likely to highly expressed in tumor cells with p53 deficiencies<ref>{{cite journal|last=Goto|first=H|coauthors=Izawa I, Li P, Inagaki M|title=Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?|journal=Cancer Sci|date=2012|volume=103|issue=7|doi=10.1111/j.1349-7006.2012.02280|pmid=22435685}}</ref><ref>{{cite journal|last=Zenvirt|first=S|coauthors=Kravchenko-Balasha N, Levitzki A|title=Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.|journal=Oncogene|date=2010|pmid=20729914}}</ref>. Even though this method of inhibition is highly targeted, recent research has shown Chk1 also has a role in the normal cell cycle<ref>{{cite journal|last=Thompson|first=R|coauthors=Eastman A|title=The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design|journal=Br J Clin Pharmacol|date=2013|volume=76|issue=3|doi= 10.1111/bcp.12139.|pmid=23593991}}</ref>. Therefore off-target effects and toxicity associated with combination therapies using CHk1 inhibitors must be considered during development of novel therapies<ref>{{cite journal|last=Dent|first=P|coauthors=Tang Y, Yacoub A, Dai Y et al|title=CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.|journal=Mol Interv.|date=2011|doi=10.1124/mi.11.2.11|pmid=21540473}}</ref> .


==See also==
==See also==

Revision as of 00:17, 4 May 2014

Template:PBB Checkpoint kinase 1, commonly referred to as Chk1 is an Serine/threonine-specific protein kinase that in humans, is encoded by the CHEK1 gene.[1][2] Chk1 coordinates the DNA damage response (DDR) and cell cycle checkpoint response[3]. Activation of Chk1 results in the initiation of cell cycle checkpoints, cell cycle arrest, DNA repair and cell death to prevent damaged cells from progressing through the cell cycle.

Discovery

In 1993, Beach and associates initially identified Chk1 as a serine/threonine kinase which regulates the G2/M phase transition in fission yeast.[4] Constitutive expression of Chk1 in fission yeast was shown to induce cell cycle arrest. The same gene called Rad27 was identified in budding yeast by Carr and associates. In 1997, homologs were identified in more complex organisms including the fruit fly, human and mouse.[5] Through these findings, it is apparent Chk1 is highly conserved from yeast to humans.[1]

Structure

Human Chk1 is located on chromosome 11 on the cytogenic band 11q22-23. Chk1 has a N-terminal kinase domain, a linker region, a regulatory SQ/TQ domain and a C-terminal domain.[5] Chk1 contains four Ser/Gln residues.[4] Chk 1 activation occurs primarily through the phosphorylation of the conserved sites, Ser-317, Ser-345 and less often at Ser-366.[4][6]

Function

Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. Two checkpoint kinase subtypes have been identified, Chk1 and Chk2. Chk1 is a central component of genome surveillance pathways and is a key regulator of the cell cycle and cell survival. Chk1 is required for the initiation of DNA damage checkpoints and has recently been shown to play a role in the normal (unperturbed) cell cycle.[5] Chk1 impacts various stages of the cell cycle including the S phase, G2/M transition and M phase.[4]

In addition to mediating cell cycle checkpoints, Chk1 also contributes to DNA repair processes, gene transcription, embryo development, cellular responses to HIV infection and somatic cell viability.[4]

S phase

Chk1 is essential for the maintenance of genomic integrity. Chk1 monitors DNA replication in unperturbed cell cycles and responds to genotoxic stress if present.[5] Chk1 recognizes DNA strand instability during replication and can stall DNA replication in order to allow time for DNA repair mechanisms to restore the genome.[4] Recently, Chk1 has shown to mediate DNA repair mechanisms and does so by activating various repair factors. Furthermore, Chk1 has been associated with three particular aspects of the S-phase, which includes the regulation of late origin firing, controlling the elongation process and maintenance of DNA replication fork stability.[4]

G2/M transition

In response to DNA damage, Chk1 is an important signal transducer for G2/M checkpoint activation. Activation of Chk1 holds the cell in the G2 phase until ready to enter the mitotic phase. This delay allows time for DNA to repair or cell death to occur if DNA damage is irreversible[7] . Chk1 must inactivate in order for the cell to transition from the G2 phase into mitosis, Chk1 expression levels are mediated by regulatory proteins.

M phase

Chk1 has a regulatory role in the spindle checkpoint however the relationship is less clear as compared to checkpoints in other cell cycle stages. During this phase the Chk1 activating element of ssDNA can not be generated suggesting an alternate form of activation. Studies on Chk1 deficient chicken lymphoma cells have shown increased levels of genomic instability and failure to arrest during the spindle checkpoint phase in mitosis.[4] Furthermore, haploinsufficient mammary epithelial cells illustrated misaligned chromosomes and abnormal segregation. These studies suggest Chk1 depletion can lead to defects in the spindle checkpoint resulting in mitotic abnormalities.

Interactions

DNA damage induces the activation of Chk1 which facilitates the initiation of the DNA damage response (DDR) and cell cycle checkpoints. The DNA damage response is a network of signaling pathways that leads to activation of checkpoints, DNA repair and apoptosis to inhibit damaged cells from progressing through the cell cycle.

Chk1 activation

Chk1 is regulated by ATR through phosphorylation, forming the ATR-Chk1 pathway. This pathway recognizes single strand DNA (ssDNA) which can be a result of UV-induced damage, replication stress and inter-strand cross linking.[4][5] Often ssDNA can be a result of abnormal replication during S phase through the uncoupling of replication enzymes helicase and DNA polymerase.[4] These ssDNA structures attract ATR and eventually activates the checkpoint pathway.

However, activation of Chk1 is not solely dependent on ATR, intermediate proteins involved in DNA replication are often necessary. Regulatory proteins such as replication protein A, Claspin, Tim/Tipin, Rad 17, TopBP1 may be involved to facilitate Chk1 activation. Additional protein interactions are involved to induce maximal phosphorylation of Chk1. Chk1 activation can also be ATR-independent through interactions with other protein kinases such as PKB/AKT, MAPKAPK and p90/RSK.[4]

Cell cycle arrest

Chk1 interacts with many downstream effectors to induce cell cycle arrest. In response to DNA damage, Chk1 primarily phosphorylates Cdc25 which results in its proteasomal degradation.[5] The degradation has an inhibitory effect on the formation of cyclin-dependent kinase complexes, which are key drivers of the cell cycle.[8] Through targeting Cdc25, cell cycle arrest can occur at multiple time points including the G1/S transition, S phase and G2/M transition.[4] Furthermore, Chk1 can target Cdc25 indirectly through phosphorylating Nek11.

WEE1 kinase and PLK1 are also targeted by Chk1 to induce cell cycle arrest. Phosphorylation of WEE1 kinase inhibits cdk1 which results in cell cycle arrest at the G2 phase.[4]

Chk1 has a role in the spindle checkpoint during mitosis thus interacts with spindle assembly proteins Aurora A kinase and Aurora B kinase.[5]

DNA repair

Recently, Chk1 has shown to mediate DNA repair mechanisms and does so by activating repair factors such as proliferating cell nuclear antigen (PCNA), FANCE, Rad51 and TLK.[4] Chk1 facilitates replication fork stabilization during DNA replication and repair however more research is necessary to define the underlying interactions.[5]

Clinical Relevance

Chk1 has a central role in coordinating the DNA damage response and therefore is an area of great interest in oncology and the development of cancer therapeutics.[9] Initially Chk1 was thought to function as a tumor suppressor due to the regulatory role it serves amongst cells with DNA damage. However, there has been no evidence of homozygous loss of function mutants for Chk1 in human tumors.[4] Instead, Chk1 has been shown to be overexpressed in a numerous tumors including breast, colon, liver, gastric and nasopharyngeal carcinoma.[4] There is a positive correlation with Chk1 expression and tumor grade and disease recurrence suggesting Chk1 may promote tumor growth.[4][5][9] Chk1 is essential for cell survival and through high levels of expressions in tumors the function may be inducing tumor cell proliferation. Studies have shown complete loss of Chk1 suppresses chemically induce carcinogenesis however Chk1 haploinsufficiency results in tumor progression.[5]

Due to the possibility of Chk1 involvement in tumor promotion, the kinase and related signaling molecules may be potentially effective therapeutic targets. Cancer therapies utilize DNA damaging therapies such as chemotherapies and ionizing radiation to inhibit tumor cell proliferation and induce cell cycle arrest.[10] Tumor cells with increased levels of Chk1 acquire survival advantages due to the ability to tolerate a higher level of DNA damage. Therefore Chk1 may contribute to chemotherapy resistance.[11] In order to optimize chemotherapies, Chk1 must be inhibited to reduce the survival advantage.[12] By inhibiting Chk1, cancer cells lose the ability to repair damaged DNA which allows chemotherapeutic agents to work more effectively. Combining DNA damaging therapies such as chemotherapy or radiation treatment with Chk1 inhibition enhances targeted cell death and provides synthetic lethality[13] . Many cancers rely on Chk1 mediated cell cycle arrest heavily especially if cancers are deficient in p53[14] . Approximately 50% of cancers possess p53 mutations illustrating the dependence that many cancers may have on the Chk1 pathway[15] [16] [17]. Inhibition of Chk1 allows selective targeting of p53 mutant cells as Chk1 levels are more likely to highly expressed in tumor cells with p53 deficiencies[18][19]. Even though this method of inhibition is highly targeted, recent research has shown Chk1 also has a role in the normal cell cycle[20]. Therefore off-target effects and toxicity associated with combination therapies using CHk1 inhibitors must be considered during development of novel therapies[21] .

See also

DNA damage checkpoints

CHEK2

References

  1. ^ a b Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (Sep 1997). "Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25". Science. 277 (5331): 1497–501. doi:10.1126/science.277.5331.1497. PMID 9278511.{{cite journal}}: CS1 maint: multiple names: authors list (link) Cite error: The named reference "pmid9278511" was defined multiple times with different content (see the help page).
  2. ^ Flaggs G, Plug AW, Dunks KM, Mundt KE, Ford JC, Quiggle MR, Taylor EM, Westphal CH, Ashley T, Hoekstra MF, Carr AM (Feb 1998). "Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes". Curr Biol. 7 (12): 977–86. doi:10.1016/S0960-9822(06)00417-9. PMID 9382850.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ McNeely, S (2014). "CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy". Pharmacol Ther. 142 (1): 1–10. doi:10.1016/j.pharmthera.2013.10.005. PMID 24140082. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  4. ^ a b c d e f g h i j k l m n o p q Zhang Y, Hunter T (2014). "Roles of Chk1 in cell biology and cancer therapy". Int. J. Cancer. 134 (5): 1013–23. doi:10.1002/ijc.28226. PMID 23613359.
  5. ^ a b c d e f g h i j Patil M, Pabla N, Dong Z (2013). "Checkpoint kinase 1 in DNA damage response and cell cycle regulation". Cell. Mol. Life Sci. 70 (21): 4009–21. doi:10.1007/s00018-013-1307-3. PMID 23508805.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Caparelli, ML (013). "Regulatory motifs in Chk1". Cell Cycle. doi:10.4161/cc.23881. PMID 23422000. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ Meuth, M (2010). "Chk1 suppressed cell death". Cell Div. doi:10.1186/1747-1028-5-21. PMID 20813042.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ (2000). "Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint". Genes Dev. 14 (12): 1448–59. PMC 316686. PMID 10859164.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ a b Goto H, Izawa I, Li P, Inagaki M (2012). "Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?". Cancer Sci. 103 (7): 1195–200. doi:10.1111/j.1349-7006.2012.02280.x. PMID 22435685.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Smith J, Tho LM, Xu N, Gillespie DA (2010). "The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer". Adv. Cancer Res. 108: 73–112. doi:10.1016/B978-0-12-380888-2.00003-0. PMID 21034966.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Liang Y, Lin SY, Brunicardi FC, Goss J, Li K (2009). "DNA damage response pathways in tumor suppression and cancer treatment". World J Surg. 33 (4): 661–6. doi:10.1007/s00268-008-9840-1. PMID 19034564.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ McNeely S, Beckmann R, Bence Lin AK (2014). "CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy". Pharmacol. Ther. 142 (1): 1–10. doi:10.1016/j.pharmthera.2013.10.005. PMID 24140082.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Toledo, L (2011). "Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs". Mol Oncol 2011. doi:10.1016/j.molonc.2011.07.002. PMID 21820372. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  14. ^ Chen, Z (2006). "Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics". Int J Cancer. PMID 17019715. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  15. ^ Maugeri-Saccà, M (2004). "Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy". Cancer Treat Rev. 39 (5): 525–533. doi:10.1016/j.ctrv.2012.10.007. PMID 23207059. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  16. ^ Tao, ZF (2006). "Chk1 inhibitors for novel cancer treatment". Anticancer Agent Med Chem. PMID 16842237. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  17. ^ Ma, CX (2011). "Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics". Trends Mol Med. PMID 21087899. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  18. ^ Goto, H (2012). "Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?". Cancer Sci. 103 (7). doi:10.1111/j.1349-7006.2012.02280. PMID 22435685. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ Zenvirt, S (2010). "Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents". Oncogene. PMID 20729914. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  20. ^ Thompson, R (2013). "The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design". Br J Clin Pharmacol. 76 (3). doi:10.1111/bcp.12139.. PMID 23593991. {{cite journal}}: Check |doi= value (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  21. ^ Dent, P (2011). "CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle". Mol Interv. doi:10.1124/mi.11.2.11. PMID 21540473. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

Further reading


Stub icon

This article on a gene on human chromosome 11 is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CHEK1&oldid=606964045"